Searchable abstracts of presentations at key conferences on calcified tissues

ba0002p33 | (1) | ICCBH2013

Patients with mutations in PHEX or FGF23 share FGF23 excess but present distinct bone and mineral metabolism features

Theret Claire , Esterle Laure , Souchon Pierre-Francois , Allain-Launay Emma , Roussey Gwennaelle , Deschenes Georges , Chaussain Catherine , Rothenbuhler Anya , Prie Dominique , Silve Caroline , Kamenicky Peter , Linglart Agnes

Mutations in PHEX and specific missense mutations of FGF23 result in elevated circulating FGF23 and hypophosphatemic rickets, respectively X-linked hypophosphatemic rickets (XLHR) and autosomal dominant HR (ADHR). FGF23, secreted by osteoblasts and osteocytes, regulates phosphate handling and vitamin D metabolism through its action on kidney. Extra renal effects of FGF23, including bone, have been very recently suspected mainly from overexpression or underexpression of FGF23 i...

ba0005oc1.5 | Clinical trials and osteoporosis treatment | ECTS2016

Secular trends in prescription incidence of different anti-osteoporotic drugs in the UK population aged 50 years or above from 1990 till 2012

van der Velde Robert , Wyers Caroline , Geusens Piet , van den Bergh Joop , de Vries Frank , Cooper Cyrus , vandeStaa Tjeerd-Pieter , Harvey Nicholas

Objective: To study the trends in prescription of different anti-osteoporotic drugs (AOD) in the UK population aged 50 years or above from 1990 till 2012.Methods: Retrospective observational study using the CPRD data link representative for the total UK population. The incidence of prescription of a specific AOD was calculated by dividing the number of prescriptions by the total person-years (py) of follow-up.Results: AOD prescript...

ba0006p048 | (1) | ICCBH2017

A rare cause of rickets

Sakka Sophia , Uday Suma , Randell Tabitha , Davies Justin H , Arya Ved Bushan , Brain Caroline , Allgrove Jeremy , Hogler Wolfgang , Shaw Nick J

Background: The development of hypophosphataemic rickets in infants fed with the elemental formula (EF) Neocate® has been recently reported. We present seven cases of exclusively Neocate-fed babies who developed hypophosphataemic rickets.Presenting problem: Three patients (P1,3,4) had incidental findings of rickets on chest X-rays, two (P2,6) developed leg deformities and rickets was confirmed on X-rays, and two (P5,6) presented with femu...

ba0007p99 | (1) | ICCBH2019

Pre and post-natal achondroplasia, retrospective series of 64 consecutives cases with analyze of the diagnostic methods and timing issues

Baujat Genevieve , Borghese Roxana , Sonigo Pascale , Bacrot Severine , Bengoa Joana , Michot Caroline , Millischer Anne-Elodie , Rondeau Sophie , Childs Beatrice , Attie-Bittach Tania , Bessieres Bettina , Salomon Laurent , Ville Yves , Bonnefont Jean-Paul , Steffann Julie , Cormier-Daire Valerie

The last years, diagnosis of achondroplasia benefited of the recent advances in prenatal imaging (including 3T-CD scan), and in invasive and non-invasive molecular screening.Objectives: To analyse stage/age, diagnosis procedures and outcome on a series of 64 consecutive cases of achondroplasia, in the French Centre of Reference for skeletal dysplasia, between 2008 and 2016.Methods: Confirmed achondroplasia were included in this sin...

ba0007p151 | (1) | ICCBH2019

The safety and efficacy of denosumab versus zoledronic acid in the treatment of pediatric osteoporosis: a randomized controlled pilot trial

Robinson Marie-Eve , Ma Jinhui , Khan Nasrin , Khatchadourian Karine , Page Marika , Konji Victor , Ann Matzinger Mary , Shenouda Nazih , Jaremko Jacob L , Zuijdwijk Caroline , Jackowski Stefan , Saleh David , MacLeay Lynn , Siminoski Kerry , Ward Leanne M

Objectives: Denosumab (Dmab) is a monoclonal antibody targeting RANKL administered by sub-cutaneous injection. Given its convenient mode of administration, our goal was to assess the safety and efficacy of Dmab compared to intravenous zoledronic acid (ZA) in pediatric osteoporosis.Methods: In this one-year pilot study (NCT02632916), children 4–16 years with low-trauma fractures due to osteoporosis were randomized 1:1 to receive ZA 0.025 mg/kg or Dma...

ba0007p152 | (1) | ICCBH2019

An evaluation of the rebound phenomenon during denosumab therapy in children with low turnover osteoporosis

Robinson Marie-Eve , Ma Jinhui , Khan Nasrin , Khatchadourian Karine , Page Marika , Konji Victor , Ann Matzinger Mary , Shenouda Nazih , Jaremko Jacob L , Zuijdwijk Caroline , Jackowski Stefan , Saleh David , MacLeay Lynn , Siminoski Kerry , Ward Leanne M

Objectives: Denosumab (Dmab) is a monoclonal antibody targeting RANKL administered by sub-cutaneous injection. Recent reports have raised concern about the ‘rebound phenomenon’ (hypercalcemia and increases in bone turnover markers, BTM) following Dmab in adults, and during treatment in children with osteogenesis imperfecta. The purpose of this report was to explore this phenomenon in children with osteoporosis associated with lower bone turnover.<p class="abstext...

ba0007lb5 | (1) | ICCBH2019

Chronic recurrent multifocal osteomyelitis in children with hypophosphatasia explained by anti-inflammatory nucleotidase activity of tissue nonspecific alkaline phosphatase in mesenchymal and hematopoietic cells

Bessueille Laurence , Briolay Anne , Como Juna , Mansouri Cylia , Gleizes Marie , El Jamal Alaeddine , Buchet Rene , Dumontet Charles , Matera Eva-Laure , Mornet Etienne , Millan Jose Luis , Fonta Caroline , Magne David

Deficiency in tissue nonspecific alkaline phosphatase (TNAP) causes hypophosphatasia (HPP), which is mainly characterized by skeletal hypomineralization. TNAP promotes mineralization by dephosphorylating the mineralization inhibitor inorganic pyrophosphate (PPi), which is generated from adenosine triphosphate (ATP) by ectonucleotide pyrophosphatase phosphodiesterase 1 (NPP1). Chronic recurrent multifocal osteomyelitis (CRMO), a sterile bone auto-inflammatory disease, has been ...

ba0003pp104 | Cell biology: osteoblasts and bone formation | ECTS2014

Overexpression of Sp7 in osteoblasts inhibits osteoblast maturation but enhances angiogenesis in bone

Komori Hisato , Miyazaki Toshihiro , Yoshida Carolina A , Komori Toshihisa

Sp7 and Runx2 are essential transcription factors for osteoblast differentiation at an early stage, and Runx2 inhibits osteoblast maturation at a late stage. However, the functions of Sp7 in bone development are not fully elucidated. Thus, we pursued the functions of Sp7 in bone development by generating osteoblast-specific Sp7 transgenic (tg) mice using 2.3 kb Col1a1 promoter. Sp7 tg mice showed osteopenia and woven-bone like structure in the cortic...

ba0004is25biog | (1) (2) | ICCBH2015

Beyond the mechanical in muscle–bone interaction

Bonewald Lynda F

Biographical DetailsDr Lynda F Bonewald is a University of Missouri, Kansas City (UMKC) Curators Professor, the Lefkowitz Professor of Oral and Craniofacial Sciences, and Director of the Mineralized Tissue/Bone Biology Research Program at the UMKC School of Dentistry, Director of the UMKC Center of Excellence in the Study of Dental and Musculoskeletal Tissues and UMKC Vice Chancellor for ...

ba0001pp62 | Bone development/growth and fracture repair | ECTS2013

Intermittent administration of parathyroid hormone (1–34) may induce the formation of cementum and bone: a histological study in rats

Vasconcelos Daniel , Marques Marcelo , Barros Silvana , Vasconcelos Any Carolina , Benatti Bruno , Novaes Pedro

The aim of this study was to evaluate the effect of anabolic PTH on periodontal repair and mandibular bone defect in rats. Fenestration defects were created unilaterally of lower first molars in Wistar rats (n=32), and both periodontal ligament and cementum were removed. Animals were treated 3 times a week and then assigned to four groups (n=8): i) C14 – placebo administration for 14 days; ii) P14 – PTH administration for 14 days; iii) C21 – pl...